Clark Estates Inc. NY Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Clark Estates Inc. NY trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,275 shares of the biopharmaceutical company’s stock after selling 3,300 shares during the quarter. Clark Estates Inc. NY’s holdings in Gilead Sciences were worth $3,377,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Kiltearn Partners LLP acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $6,087,000. Townsquare Capital LLC boosted its holdings in Gilead Sciences by 14.4% in the 3rd quarter. Townsquare Capital LLC now owns 134,964 shares of the biopharmaceutical company’s stock worth $11,315,000 after buying an additional 16,996 shares during the last quarter. Cadence Bank raised its holdings in shares of Gilead Sciences by 3.2% during the third quarter. Cadence Bank now owns 122,969 shares of the biopharmaceutical company’s stock valued at $10,310,000 after acquiring an additional 3,800 shares during the last quarter. Avestar Capital LLC lifted its position in shares of Gilead Sciences by 28.4% in the third quarter. Avestar Capital LLC now owns 6,935 shares of the biopharmaceutical company’s stock valued at $581,000 after acquiring an additional 1,534 shares in the last quarter. Finally, Brooklyn Investment Group acquired a new stake in shares of Gilead Sciences in the third quarter worth approximately $444,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.0 %

Gilead Sciences stock opened at $91.35 on Wednesday. The firm has a market capitalization of $113.85 billion, a P/E ratio of 1,015.00, a P/E/G ratio of 2.81 and a beta of 0.17. The stock’s fifty day simple moving average is $87.74 and its 200-day simple moving average is $77.31. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the previous year, the company posted $2.29 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.37 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.37%. Gilead Sciences’s payout ratio is currently 3,422.22%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,947 shares of company stock valued at $4,968,674 over the last quarter. 0.29% of the stock is owned by insiders.

Wall Street Analyst Weigh In

GILD has been the subject of several recent research reports. Barclays increased their price objective on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. Robert W. Baird raised their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Citigroup assumed coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective for the company. Royal Bank of Canada raised their target price on shares of Gilead Sciences from $81.00 to $84.00 and gave the stock a “sector perform” rating in a research note on Monday, November 18th. Finally, UBS Group upped their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Twelve equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.41.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.